RhoVac ApS | LinkedIn

Press Release

RhoVac Participates in BIO Europe Digital

Oct 26, 2020

Lund, October 26, 2020. RhoVac AB (“RhoVac”) announces today that it is participating this week in the partnering event BIO Europe 2020 Digital.

This week the digital version of the massive pharmaceutical partnering conference BIO Europe is held with participation from RhoVac. The program features plenum sessions on contemporary common interest topics in the industry, but the emphasis is on partnering.

RhoVac’s CEO, Anders Månsson, comments: “RhoVac certainly maintains a regular dialogue with its potential partners also outside of digital congresses, but digital conferences like BIO Europe obviously provides us with an opportunity to ‘mass market’ our company and the RV001, and there is certainly a great interest out there.”

About RhoVac AB

RhoVac was established as a private company in Denmark in 2007. Under this company, the basic development steps for the drug candidate RV001 were undertaken. In 2015 the Swedish RhoVac AB was formed, which is now headquartered and in 2016 the company was listed on the then Aktietorget in Sweden (now Spotlight Stock Market). RhoVac has passed the early stages of development. In 2018, the first clinical trial (phase I / II) was completed in prostate cancer, demonstrating that RV001 has good safety and is well tolerated, and that the drug provides the expected immune response that will exert its effect on the cancer cells. The strong immune response has also been shown to last over time. Therefore, RhoVac is launching a clinical phase IIb trial that will include at least 175 prostate cancer patients. The study is designed to show, with statistical significance, the effect of RV001 in preventing disease progression in prostate cancer after surgery or radiation to the primary tumor. RhoVac is listed on Spotlight, Sweden, a Multilateral Trading Facility (MTF) since March 2016. The share is traded under the ticker RHOVAC. Read more at www.rhovac.com